Rational drug design and HIV: hopes and limitations.
Goody
R S
RS
Max-Planck-Institut für Molekulare Physiologie, Dortmund, Germany.
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001665:Binding Sites / Q000187:drug effects; D015195:Drug Design; D004352:Drug Resistance, Microbial; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase